BRPI0808897B8 - uso de um pó compreendendo tmc278, disperso em um copolímero de vinilpirrolidona e acetato de vinila e solução supersaturada de tmc278 - Google Patents

uso de um pó compreendendo tmc278, disperso em um copolímero de vinilpirrolidona e acetato de vinila e solução supersaturada de tmc278

Info

Publication number
BRPI0808897B8
BRPI0808897B8 BRPI0808897A BRPI0808897A BRPI0808897B8 BR PI0808897 B8 BRPI0808897 B8 BR PI0808897B8 BR PI0808897 A BRPI0808897 A BR PI0808897A BR PI0808897 A BRPI0808897 A BR PI0808897A BR PI0808897 B8 BRPI0808897 B8 BR PI0808897B8
Authority
BR
Brazil
Prior art keywords
tmc278
dispersed
vinylpyrrolidone
copolymer
powder
Prior art date
Application number
BRPI0808897A
Other languages
English (en)
Inventor
Van Gyseghem Elke
René Jaak Van Den Mooter Guy
Elvire Colette Baert Lieven
Jozef Maria Van Remoortere Peter
Original Assignee
Janssen R & D Ireland
Janssen Sciences Ireland Uc
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38055251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0808897(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland, Janssen Sciences Ireland Uc, Tibotec Pharm Ltd filed Critical Janssen R & D Ireland
Publication of BRPI0808897A2 publication Critical patent/BRPI0808897A2/pt
Publication of BRPI0808897B1 publication Critical patent/BRPI0808897B1/pt
Publication of BRPI0808897B8 publication Critical patent/BRPI0808897B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

pós para reconstituição. a presente invenção refere-se a pós para reconstituição compreendendo o nnrti tmc278 disperso em certos polímeros solúveis em água, que podem ser aplicados no tratamento de infecção por hiv.
BRPI0808897A 2007-03-14 2008-03-14 uso de um pó compreendendo tmc278, disperso em um copolímero de vinilpirrolidona e acetato de vinila e solução supersaturada de tmc278 BRPI0808897B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07104082 2007-03-14
EP07104082.8 2007-03-14
PCT/EP2008/053056 WO2008110619A1 (en) 2007-03-14 2008-03-14 Powders for reconstitution

Publications (3)

Publication Number Publication Date
BRPI0808897A2 BRPI0808897A2 (pt) 2014-09-02
BRPI0808897B1 BRPI0808897B1 (pt) 2020-10-20
BRPI0808897B8 true BRPI0808897B8 (pt) 2021-05-25

Family

ID=38055251

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808897A BRPI0808897B8 (pt) 2007-03-14 2008-03-14 uso de um pó compreendendo tmc278, disperso em um copolímero de vinilpirrolidona e acetato de vinila e solução supersaturada de tmc278

Country Status (18)

Country Link
US (1) US8916558B2 (pt)
EP (1) EP2043608B1 (pt)
JP (1) JP5554571B2 (pt)
KR (1) KR101580297B1 (pt)
CN (1) CN101636149B (pt)
AP (1) AP2964A (pt)
AR (2) AR065720A1 (pt)
AU (1) AU2008225774B2 (pt)
BR (1) BRPI0808897B8 (pt)
CA (1) CA2676981C (pt)
CL (1) CL2008000746A1 (pt)
ES (1) ES2535162T3 (pt)
IL (1) IL199874A (pt)
MX (1) MX2009009743A (pt)
RU (1) RU2477133C2 (pt)
TW (1) TWI494133B (pt)
WO (1) WO2008110619A1 (pt)
ZA (1) ZA200906344B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
AU2012241726C1 (en) * 2011-04-15 2017-09-14 Janssen Pharmaceutica Nv Freeze dried drug nanosuspensions
JP6301339B2 (ja) * 2012-09-27 2018-03-28 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 少なくとも１種の水溶性ビタミンｅ誘導体および少なくとも１種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤
US20210000823A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
TW202408580A (zh) * 2022-04-22 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 冷凍乾燥組成物(二)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US5182111A (en) 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
EP0489181B1 (en) 1990-07-19 1996-10-02 Otsuka Pharmaceutical Co., Ltd. Solid preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5837747A (en) 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
ES2138624T3 (es) 1992-05-13 2000-01-16 Wellcome Found Combinaciones terapeuticas.
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
KR100801588B1 (ko) 1999-09-21 2008-02-05 스키에파마 캐나다 인코포레이티드 생물학적 유효 물질의 표면 변형된 미립자 조성물
AU775360B2 (en) 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
US6743446B2 (en) 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
WO2001074329A2 (en) 2000-03-30 2001-10-11 Bristol-Myers Squibb Company Sustained release beadlets containing stavudine
US20040115268A1 (en) 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
ATE444060T1 (de) 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AU2002364701B8 (en) 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
WO2004016581A1 (en) 2002-08-09 2004-02-26 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7497855B2 (en) 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
ES2286471T3 (es) 2002-11-08 2007-12-01 Glaxo Group Limited Composiciones farmaceuticas antivirales.
BR0316209A (pt) 2002-11-15 2005-09-27 Tibotec Pharm Ltd Indolpiridìnio substituìdo como compostos antiinfecciosos
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
KR20110132482A (ko) 2003-02-07 2011-12-07 얀센 파마슈티카 엔.브이. Ｈｉｖ 감염 예방용 피리미딘 유도체
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
WO2005123076A2 (en) 2004-06-08 2005-12-29 Vertex Pharmaceuticals, Inc. Pharmaceutical compositions
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EA013686B1 (ru) 2004-09-02 2010-06-30 Янссен Фармацевтика Н.В. Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
KR101284361B1 (ko) 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
EP2623095A1 (en) 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TW200710091A (en) * 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US20060269475A1 (en) 2005-04-11 2006-11-30 Ryu Wonhyoung Multi-layer structure having a predetermined layer pattern including an agent
WO2006131806A2 (en) 2005-06-07 2006-12-14 Pfizer Products Inc. Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
US20070026073A1 (en) 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
SI1981506T1 (sl) 2006-01-20 2013-08-30 Janssen R&D Ireland Dolgoročno zdravljenje infekcije HIV s TCM278
PT2029110E (pt) 2006-06-06 2011-11-23 Tibotec Pharm Ltd Processo para preparar formulações secas por atomização de tmc125
MX2009000158A (es) 2006-06-23 2009-01-23 Tibotec Pharm Ltd Suspensiones acuosas de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil ]-amino]-2-pirimidinil]-amino]-benzonitrilo.
US20080081064A1 (en) 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
ES2437331T3 (es) 2007-07-12 2014-01-10 Janssen R&D Ireland Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
WO2009046299A2 (en) 2007-10-04 2009-04-09 Boston Scientific Scimed, Inc Implantable drug depot for intrathecal drug delivery system for pain management
EP2358198A4 (en) 2008-10-24 2012-11-14 Concert Pharmaceuticals Inc HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES

Also Published As

Publication number Publication date
KR20090119964A (ko) 2009-11-23
AR114086A2 (es) 2020-07-22
CL2008000746A1 (es) 2008-09-22
IL199874A0 (en) 2010-04-15
RU2009137911A (ru) 2011-04-20
BRPI0808897B1 (pt) 2020-10-20
BRPI0808897A2 (pt) 2014-09-02
EP2043608A1 (en) 2009-04-08
US20100120795A1 (en) 2010-05-13
AR065720A1 (es) 2009-06-24
KR101580297B1 (ko) 2015-12-24
EP2043608B1 (en) 2015-01-21
AU2008225774B2 (en) 2014-04-10
CA2676981C (en) 2015-01-13
WO2008110619A1 (en) 2008-09-18
TWI494133B (zh) 2015-08-01
AP2009004969A0 (en) 2009-10-31
IL199874A (en) 2016-02-29
AU2008225774A1 (en) 2008-09-18
JP2010520918A (ja) 2010-06-17
RU2477133C2 (ru) 2013-03-10
CN101636149A (zh) 2010-01-27
CN101636149B (zh) 2014-08-06
MX2009009743A (es) 2009-09-23
CA2676981A1 (en) 2008-09-18
ZA200906344B (en) 2015-04-29
TW200911303A (en) 2009-03-16
ES2535162T3 (es) 2015-05-05
US8916558B2 (en) 2014-12-23
JP5554571B2 (ja) 2014-07-23
AP2964A (en) 2014-09-30

Similar Documents

Publication Publication Date Title
BRPI0808897B8 (pt) uso de um pó compreendendo tmc278, disperso em um copolímero de vinilpirrolidona e acetato de vinila e solução supersaturada de tmc278
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
MX2013003137A (es) Nanocapsulas que contienen microemulsiones.
WO2013142124A8 (en) Solid forms of a thiophosphoramidate nucleotide prodrug
WO2017004534A3 (en) Microbiome-compatible cosmetics
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
MX2014009219A (es) Compuestos de purinona como inhibidores de quinasas.
TW200621268A (en) Antimicrobial copolymers and uses thereof
BR112018011501A2 (pt) copolímeros em bloco de formação de camada de polieletrólito e composições e usos dos mesmos
SG10201803331PA (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
BR112015014760A2 (pt) complexo de zinco-aminoácido com cisteína
WO2010110685A8 (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
IL186104A (en) Phosphoramidate History of Nucleoside Compounds
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
WO2009002425A3 (en) Solubilized formulation of docetaxel without tween 80
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
EA201270264A1 (ru) Лечение метастазов в головной мозг ингибиторами рецепторов эндотелина в комбинации с цитотоксическим химиотерапевтическим средством
TR200806298A2 (tr) Farmasötik formülasyon
WO2014179615A3 (en) Biodegradable copolymers, forming and using same
IN2014DE01722A (pt)
PH12018500368A1 (en) Preparations containing amorphous emodepside
EP3438143A4 (en) COPOLYMER, SAID COPOLYMER THICKENER AND COSMETIC PREPARATION IN WHICH THIS COPOLYMER IS MIXED
MX2011010547A (es) Composiciones farmaceuticas estables de diclofenaco.
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF